Journal of Liver

Primary biliary cholangitis (PBC) in China and finding a novel method to treat ursodeoxycholic acid (UDCA) non-responders

4^th International Conference on Hepatology

April 27-28, 2017 Dubai, UAE

Lifeng Wang and China Fu-Sheng Wang

Beijing 302 Hospital, China

Posters & Accepted Abstracts: J Liver

Abstract:

Statement of the Problem: Primary biliary cholangitis (PBC) is a chronic cholestatic liver disease characterized by immunomediated destruction of small and medium-sized intrahepatic bile ducts. For a long time, PBC was regarded as a rare disease in China. Although the prevalence and incidence of PBC in China is still not clear, the number of patients are increasing, which makes it urgent to learn more about the characteristics of the disease in China. Meanwhile, ursodeoxycholic acid (UDCA) treatment is an effective medical therapy for patients with PBC, however, 40% of PBC patients showed an incomplete response to the UDCA therapy. Mesenchymal stem cells (MSC) represent a promising tool for cell-based therapies of autoimmune diseases, with few adverse effects, because of their immunosuppressive properties on both innate and adaptive immunity and their ability to differentiate into multiple lineages. Another issue of our concern is, could MSC transplantation be a novel method to treat those UDCA non-responders. Methodology & Theoretical Orientation: By collecting the articles published by Chinese scientists or doctors, we reviewed Chinese achievements from diagnosis to treatment about PBC. In addition, based on 7 PBC patients with non-responds to UDCA, we investigated the safety and efficacy of umbilical cord-derived mesenchymal stem cell (UC-MSC) transfusion on those patients. Findings: The number of Chinese patients with PBC has increased each year and now there is a significant and important basic clinical research on PBC in China, with major contributions in diagnostic criteria, treatment, and on basic biology. UC-MSC transfusion is feasible and well tolerated in PBC patients with non-responds to UDCA. Conclusion & Significance: Chinese hepatologists and scientists are now focusing their efforts on PBC. UC-MSC could be a novel therapeutic approach for UDCA non-responders in the near future

Biography :

Email: biowanglf@163.com